Therapeutics and COVID-19: living guideline [Internet]

Excerpt

The WHO Therapeutics and COVID-19: living guideline contains the most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. It is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges.

The latest version (version 13, published 13 January 2023) contains important updates to recommendations which relate to:

** UPDATED ** the strong recommendation for the use of nirmatrelvir-ritonavir in patients with non-severe illness at the highest risk of hospitalization (published 22 April 2022, updated 13 January 2023) has been updated with new recommendation regarding use of nirmatrelvir-ritonavir during pregnancy and breastfeeding.

** UPDATED **the strong recommendation against the use of casirivimab-imdevimab in patients with COVID-19 (first published 24 September 2021, updated 03 March 2022, updated 16 Sept 2022, updated 13 January 2023) has been updated with new evidence of the reduction of effectiveness of casirivimab-imdevimab against circulating Omicron variants.

** UPDATED ** the strong recommendation against the use of sotrovimab in patients with non-severe COVID-19 (first published 14 January 2022, updated 16 Sept 2022, updated 13 January 2023) with new evidence of the reduction of effectiveness of sotrovimab against circulating Omicron variants.

Guidelines regarding the use of drugs to prevent (rather than treat) COVID-19 are included in a separate document, WHO Living guideline: Drugs to prevent COVID-19, that can be accessed via an online platform and in pdf format (or click ‘PDF’ in top right corner of online platform).

Guidelines regarding the clinical management of COVID-19 patients are included in a further document, COVID-19 Clinical management: Living guideline, that can be accessed via an online platform and in pdf format (or click ‘PDF’ in top right corner of online platform).